CXCL12 and cancer: This is because autocrine overexpression of CXCL12 in some tumors may be more sensitive to CXCR4 antagonists by competing with CXCL12 for receptor binding, meaning that they may be more suitable for the application of chemokine-based anti-cancer therapies [112].